News

The research collaboration will integrate Forge’s expertise in metalloenzymes with Active Motif’s knowledge in epigenetics and related technologies. Under the alliance, the companies intend to validate emerging epigenetic

Stannsoporfin is a first in class heme oxygenase inhibitor that inhibits the formation of bilirubin and is in development for the treatment of hyperbilirubinemia in newborns. The study

AsiDNA breaks the cycle of tumor DNA repair to speed up cancer cell death. DNA Therapeutics was acquired for an upfront payment of €1.7m paid at closing by

Earlier this year, AHF filed a federal lawsuit against Gilead Sciences and two other defendants in U.S. District Court, Northern District of California. It alleged drug patent manipulation

The designation gives the company 10 years of marketing exclusivity in European Union member countries if the product is approved. Oxigene president and CEO William Schwieterman said: "This

First shipments of this new store branded product have been initiated and represents a first-to-market accomplishment for Perrigo and Allergan. These products are packaged and marketed as store

CINQAIR is administered by intravenous (IV) infusion at a weight-based dose of 3 mg/kg once every four weeks. The treatment is expected to become commercially available to patients,

Close to 20 percent of breast cancers are triple-negative, a type of tumor that lacks the three most common receptors that fuel most breast cancer growth. These tumors

The EMA will now initiate its review of the XELJANZ MAA. This application provides additional information to the original MAA submission, including data from the Phase 3 ORAL